Background: Acute kidney injury (AKI) and chronic kidney disease (CKD) share a fundamental disruption: metabolic dysfunction. Methods: A literature review was performed to determine the metabolic changes that occur in AKI and CKD as well as potential therapeutic targets related to these changes. Results: In AKI, increased energy demand in proximal tubular epithelial cells drives a shift from fatty acid oxidation (FAO) to glycolysis. Although this shift offers short-term support, it also heightens cellular vulnerability to further injury. As AKI progresses to CKD, metabolic disruption intensifies, with both FAO and glycolysis becoming downregulated, exacerbating cellular damage and fibrosis. These metabolic alterations are governed by shifts in gene expression and protein signaling pathways, which can now be precisely analyzed through advanced omics and histological methods. Conclusions: This review examines these metabolic disturbances and their roles in disease progression, highlighting therapeutic interventions that may restore metabolic balance and enhance kidney function. Many metabolic changes that occur in AKI and CKD can be utilized as therapeutic targets, indicating a need for future studies related to the clinical utility of these therapeutics.
Background/Objectives: Adults with congenital heart disease (ACHD) are at high risk for late cardiac sequelae and hypertension (HTN). Ambulatory blood pressure monitoring (ABPM) is superior to office measurements in reproducibility, association with cardiovascular outcomes, and detection of masked and white coat HTN (WCH). The utility of ABPM in the ACHD population is not well studied. This study aims to determine the prevalence of hypertension in the ACHD population and evaluate the utility of ABPM in diagnosing hypertension in the ACHD population. Methods: This is a single-center retrospective analysis of ACHD patients who completed ABPM from 2021 to 2024. Results: Forty ACHD patients underwent ABPM during the study period. Twenty-nine (73%) had hypertension (HTN) in clinic. On ABPM, nine (23%) were confirmed normotensive, 15 (38%) had white coat hypertension (WCH), 14 (35%) were confirmed hypertensive, and two (5%) had masked HTN. There was a 33% decrease in patients meeting criteria for HTN on ABPM compared to in clinic (p = 0.002). Ten patients with HTN on ABPM had follow-up, during which seven (70%) had improved clinic blood pressure. One patient (2.5%) had an antihypertensive removed following WCH diagnosis on ABPM. Conclusions: ABPM is a useful way to diagnose and monitor hypertension in the ACHD population. Based on ABPM, many patients (43%) were found to have either WCH or masked HTN, and 15% had their HTN stage reclassified. ABPM results led to 33% of patients having subsequent medication adjustment. Data from ABPM can help optimize medical management, in turn reducing cardiac strain and acquired heart disease risk in ACHD patients.